Aimaz Afrough

Apr 11, 2024 | nature.com | Aimaz Afrough |Doris Hansen |Surbhi Sidana |Lauren C. Peres |Danai Dima |Joseph McGuirk | +6 more

Idecabtagene vicleucel (ide-cel) the first FDA-approved gene therapy for relapsed refractory multiple myeloma (RRMM). However, its administration presents challenges in logistical management, selecting bridging therapy (BT), and customizing T-cell manufacturing, a complex process spanning several weeks [1]. In the KarMMa trial, BT was allowed but limited to specific prior drug classes (e.g., dexamethasone, cyclophosphamide (Cy), daratumumab, carfilzomib, bortezomib, or pomalidomide) [2].